Authors: Schwaab, T Lewis, LD Cole, BF Deo, Y Fanger, MW Wallace, P Guyre, PM Kaufman, PA Heaney, JA Schned, AR Harris, RD Ernstoff, MS

Citation: T. Schwaab et al., Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu, J IMMUNOTH, 24(1), 2001, pp. 79-87

Authors: Pullarkat, V Deo, Y Link, J Spears, L Marty, V Curnow, R Groshen, S Gee, C Weber, JS

Citation: V. Pullarkat et al., A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu, CANCER IMMU, 48(1), 1999, pp. 9-21